en.Wedoany.com Report on Mar 24th, Insilico Medicine announced a strategic drug R&D collaboration with Japan's ASKA Pharmaceutical Co., Ltd. Leveraging Insilico's self-developed AI-driven target discovery engine, PandaOmics, the partnership will focus on challenging gynecological diseases such as endometriosis, uterine fibroids, and adenomyosis, aiming to identify and explore innovative targets with drug development potential.
According to the cooperation agreement, Insilico Medicine will utilize its artificial intelligence platform to conduct in-depth multi-omics data analysis on the aforementioned gynecological diseases, mining key targets closely related to disease onset and progression. ASKA Pharmaceutical will contribute its expertise and experience in drug R&D and commercialization within the gynecology and internal medicine fields to advance the identified targets towards clinical candidate drugs.
Endometriosis, uterine fibroids, and adenomyosis are common and difficult-to-treat diseases in gynecology, with a long-standing lack of efficient and safe treatment options. Traditional drug R&D is limited by insufficient understanding of disease mechanisms, resulting in low target discovery efficiency. Insilico Medicine's PandaOmics engine integrates multi-dimensional data such as genomics and proteomics, enabling the screening of targets with potential druggability from vast biological information, significantly enhancing the front-end efficiency of new drug discovery.
ASKA Pharmaceutical is a Japanese pharmaceutical company specializing in internal medicine and obstetrics/gynecology, with extensive experience in gynecological drug R&D and clinical development. This collaboration combines AI-powered target discovery capabilities with industrialized drug development expertise, holding promise for bringing new therapeutic options to the field of gynecological diseases.
Insilico Medicine stated that this collaboration represents a significant expansion of its AI drug discovery platform's application in the field of gynecological diseases. As AI technology continues to permeate areas such as target discovery, molecule generation, and clinical prediction, cross-regional pharmaceutical collaborations are becoming a new paradigm for advancing new drug R&D.
